Repeated Intravenous Administration of Liposome-Encapsulated Muramyl Tripeptide-Phosphatidyl-Ethanolamine Diminishes Cytotoxic Potential of Subpopulations of Rat Liver Macrophages

References

• Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structure requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 1974; 59: 1317
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Erickson K. L., Schroit A. J., Fogler W. E., Fidler I. J. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983; 43: 2010
   PubMed Web of Science ®Google Scholar
• Xu Z., Fidler I. J. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide. Cancer Immunol. Immunother. 1984; 18: 118
   PubMedGoogle Scholar
• Fidler I. J., Fan D., Ichinose H. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyl tripeptide phosphatidylethanolamine and interferon gamma. Invasion Metastasis 1989; 9: 75
   PubMedGoogle Scholar
• Phillips N. C., Chedid L., Bernard J. M., Level M., Lefrancier P. Induction of murine macrophage tumoricidal activity and treatment of experimental pulmonary metastases by liposomes containing lipophilic muramyl dipeptide analogs. J. Biol. Response Mod. 1987; 6: 678
   PubMedGoogle Scholar
• Talmadge J. E., Lenz B. F., Klabansky R., Simon R., Riggs C, Guo S., Oldham R. K., Fidler I. J. Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res. 1986; 46: 1160
   PubMedGoogle Scholar
• MacEwen E. G., Kurzman I. D., Rosenthal R. C., et al. Therapy of osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl. Cancer Inst. 1989; 81: 935
   PubMed Web of Science ®Google Scholar
• Poste G., Bucana C, Raz A., Bugelski P., Kirsh R., Fidler I. J. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res. 1982; 42: 1412
   PubMed Web of Science ®Google Scholar
• Brodt P., Blore J., Phillips N. C., Munzer J. S., Rioux J. D. Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipetide. Cancer Immunol. Immunother. 1989; 28: 54
   PubMedGoogle Scholar
• Hoedemakers R. M. J., Vossebeld P. J. M., Daemen T., Scherphof G. L. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides. J. Immunother. 1993; 13: 252
   Google Scholar
• Phillips N. C. Kupffer cells and liver metastasis - optimization and limitation of activation of tumoricidal activity. Cancer Metastasis Rev. 1989; 8: 231
   PubMedGoogle Scholar
• Phillips N. C., Tsao M. Inhibition of experimental liver tumor growth in mice by liposomes containing a lipophilic muramyl dipeptide derivative. Cancer Res. 1989; 49: 936
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Tsao M-S. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice. Cancer Immunol. Immunother. 1991; 33: 85
   PubMed Web of Science ®Google Scholar
• Daemen T., Dontje B., Veninga A., Scherphof G. L., Oosterhuis W. L. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Selec. Cancer Ther 1990; 6: 63
   PubMedGoogle Scholar
• Fidler I. J. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol. Immunother. 1986; 21: 169
   PubMed Web of Science ®Google Scholar
• Hoedemakers R. M. J., Daemen T., Scherphof G. L. Tumorcytolytic activity and TNF secretion of the rat liver macrophage population after intravenous administration of liposome-encapsulated MDP. Cells of the hepatic sinusoid, E Wisse, D L Knook, R S McCusky. The Kupffer Cell Foundation, RijswijkThe Netherlands 1991; Vol. III
   Google Scholar
• Fidler I. J. Macrophages and metastasis - a biological approach to cancer therapy. Cancer Res. 1985; 45: 4714
   PubMed Web of Science ®Google Scholar
• Harms G., Van Goor H., Koudstaal J., De Ley L., Hardonk M. J. Immuno-histochemical demonstration of DNA-incorporated 5-bromodeoxyuridine in frozen and plastic embedded sections. Histochem 1986; 85: 139
   Google Scholar
• Dijkstra C. D., Dopp E. A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: Distinct macrophage subpopulations in the rat recognized by monoclonal antibodies EDI, ED2 and ED3. Immunology 1985; 54: 589
   PubMed Web of Science ®Google Scholar
• Stet R. J. M., Rozing J., Majoor G. D., Kroese F. G. M., Opstelten D., Nieuwenhuis P. HIS 19: A monoclonal antibody recognizing a class II polymorphic determinant only absent on RTln class II antigens. Transpl. Proc. 1985; XVII-3, 1829
   Google Scholar
• Daemen T., Huitema S., Koudstaal J., Scherphof G. L., Hardonk M. J. Population kinetics of rat liver macrophages after intravenous administration of liposome-encapsulated MDP. Cells of the hepatic sinusoid, E Wisse, D L Knook, K Decker. The Kupffer Cell Foundation, RijswijkThe Netherlands 1989; Vol. II: 400–405
   Google Scholar
• Freeman H. On the encoding of arbitrary geometric configurations. IEEE Trans. Elec. Computers 1961; EC-10: 260
   Google Scholar
• Cruz-Orive L. M. Estimating sphere size distributions from slabs. J. Microsc. 1983; 131: 265
   Web of Science ®Google Scholar
• Daemen T., Veninga A., Roerdink F. H., Scherphof G. L. In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res. 1986; 46: 4330
   PubMed Web of Science ®Google Scholar
• Ding A. H., Nathan C. F., Stuehr D. J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 1988; 141: 2407
   PubMed Web of Science ®Google Scholar
• Damoiseaux J. G. M. C. Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody EDI. Macrophage heterogeneity in the rat. PhD-thesis, Free University Amsterdam, The Netherlands 1991; 75–90
   Google Scholar
• Hardonk M. J., Huitema S., Koudstaal J. Immunohistochemical methods in the study of liver sinusoidal cells. Cells of the hepatic sinusoid, E Wisse, D L Knook, K Decker. The Kupffer Cell Foundation, RijswijkThe Netherlands 1989; Vol. II: 483–487
   Google Scholar
• Kleinerman E. S., Kurzrock R., Wyatt D., et al. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant t-interferon. Cancer Res. 1986; 46: 5401
   PubMed Web of Science ®Google Scholar
• Phillips N. C., Rioux J., Tsao M-S. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. Hepatology 1988; 8: 1046
   PubMed Web of Science ®Google Scholar
• Creaven P. J., Cowens J. W., Brenner D. E., Dadey B. M., Han T., Cushman M. K., et al. Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer. J. Biol. Response Mod. 1990; 9: 492
   PubMedGoogle Scholar
• Murray J. L., Kleinerman E. S., Cunningham J. E., Tatom J. R., Andrejcio K., Krakoff I. H., et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. J. Clin. Oncol. 1989; 7: 1915
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Jia S-F, Griffin J., Seibel N. L., Benjamin R. S., Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 1992; 10: 1310
   PubMed Web of Science ®Google Scholar
• Sumaroka M. V., Litvinov I. S., Khaidukov S. V., Golovina T. N., Kamraz M. V., Ivanov V. T., et al. Muramyl peptide-binding sites are located inside target cells. F. E. B. S. 1991; 295: 48
   PubMedGoogle Scholar
• Utsugi T., Dinney C. P. N., Killion J. J., Fidler I. J. In situ activation of mouse macrophages and therapy of spontaneous renal cell cancer metastasis by liposomes containing the lipopeptide CGP 31362. Cancer Immunol. Immunother. 1991; 33: 375
   PubMedGoogle Scholar
• Key M. E., Talmadge J. E., Fogler W. E., Bucana C, Fidler I. J. Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J. Natl. Cancer Inst. 1982; 69: 1189
   Google Scholar
• Scherphof G. L., Roerdink F., Dijkstra J., Ellens H., DeZanger R., Wisse E. Uptake of liposomes by rat and mouse hepatocytes and Kupffer cells. Biol. Cell 1983; 47: 47
   Web of Science ®Google Scholar
• Daemen T., Veninga A., Roerdink F. H., Scherphof G. L. Endocytic and tumoricidal heterogeneity of rat liver macrophage subpopulations. Select Cancer Ther. 1989; 5: 157
   PubMedGoogle Scholar
• Sleyster E. C., Knook D. L. Relation between localization and function of rat liver Kupffer cells. Lab Invest 1982; 47: 484
   PubMed Web of Science ®Google Scholar
• Lazar G., van Galen M., Scherphof G. L. Gadolinium chloride-induced shifts in intrahepatic distributions of liposomes. Biochem. Biophys. Acta 1989; 1011: 97
   PubMedGoogle Scholar
• Hoedemakers R. M. J., Morselt H. W. M., Scherphof G. L., Daemen T. Secretion pattern of the rat liver macrophage population following activation with liposomal muramyl dipeptide in vivo and in vitro. J. Immunotherapy 1994; 15: 265
   Google Scholar
• Barratt G. M., Raddassi K., Petit J-F, Tenu J-P. MDP and LPS act synergistically to induce arginine-dependent cytostatic activity in rat alveolar macrophages. Int. J. Immunopharmacol. 1991; 13: 159
   PubMed Web of Science ®Google Scholar
• Drapier J-C, Wietzerbin J., Hibbs J. B., Jr. Interferon-gamma and tumor necrosis factor induce the 1-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol. 1988; 18: 1587
   PubMed Web of Science ®Google Scholar
• Jorens P. G., van Overveld F. J., Bult H., Vermeire P. A., Herman A. G. MDP and GM-CSF enhance interferon-gamma-induced nitric oxide preoduction by rat alveolar macrophages. Agents Actions 1993; 38: 100
   PubMedGoogle Scholar
• Karck U., Peters T., Decker K. The release of tumor necrosis factor from endotoxin-stimulated rat Kupffer cells is regulated by prostaglandin E2 and dexamethasone. J. Hepatol. 1988; 7: 352
   PubMedGoogle Scholar
• Zuckerman S. H., Evans G. F., Snyder Y. M., Roeder W. D. J. Endotoxin-macrophage interaction: post-translational regulation of tumor necrosis factor expression. J. Immunol. 1989; 143: 1223
   PubMed Web of Science ®Google Scholar